 |
 |

Therapeutic Usefulness of Propoxyphene Napsylate in Narcotic Addiction
Donald R. Jasinski, MD;
Jeffry S. Pevnick, MD;
Stewart C. Clark, MD, PhD;
John D. Griffith, MD
Arch Gen Psychiatry. 1977;34(2):227-233.
Abstract
The maximum doses of propoxyphene napsylate used to treat heroin addicts produce a degree of morphine-like activity equal to that produced by 20 to 25 mg/day of subcutaneously given morphine or 10 mg/day orally given methadone. This degree of activity would be sufficient to ameliorate abstinence even in patients dependent on large doses of narcotics—an observation that supports the utility of propoxyphene napsylate in detoxification. On the other hand, only patients taking 10 mg/day or less of parenterally administered heroin could be maintained on maximum subtoxic levels of propoxyphene napsylate without abstinence signs or symptoms suggesting that propoxyphene napsylate would be less useful in maintenance therapy.
Author Affiliations
From the Addiction Research Center, Division of Research, National Institute on Drug Abuse, Lexington, Ky. Dr Clark is now with the University of Calgary (Alberta) Faculty of Medicine.
Footnotes
Accepted for publication March 22, 1976.
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Clonidine in Morphine Withdrawal: Differential Effects on Signs and Symptoms
Jasinski et al.
Arch Gen Psychiatry 1985;42:1063-1066.
ABSTRACT
Propoxyphene in Children With Iatrogenic Morphine Dependence: A Review of the Literature With Two Additional Cases
Hasday and Weintraub
Arch Pediatr Adolesc Med 1983;137:745-748.
ABSTRACT
Propoxyphene for Maintenance Treatment of Narcotic Addiction
Woody et al.
Arch Gen Psychiatry 1981;38:898-900.
ABSTRACT
Outpatient Treatment and Outcome of Prescription Drug Abuse
Tennant
Arch Intern Med 1979;139:154-156.
ABSTRACT
Human Pharmacology and Abuse Potential of the Analgesic Buprenorphine: A Potential Agent for Treating Narcotic Addiction
Jasinski et al.
Arch Gen Psychiatry 1978;35:501-516.
ABSTRACT
|